InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,616.84
(
-0.32%
)
US TECH 100
18,992.00
(
-1.08%
)
Dow Jones
41,240.52
(
0.16%
)
Brent Oil
80.39
(
0.15%
)
Bitcoin
62,757.49
(
-0.19%
)
Post# of 252977
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

puravida

Send PM Follow Ignore
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

puravida

Re: None

Thursday, 06/27/2019 8:30:13 AM

Thursday, June 27, 2019 8:30:13 AM

Post# of 252977
DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication

Company to Host Conference Call at 9am EST



http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up